Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high34.82 22/10/15
52 week low17.25 26/09/16
52 week change -6.13 (-23.44%)
4 week volume8,849,606 03/09/16

Latest NewsMore

Director Deals - Allergy Therapeutics PLC (AGY)

Peter Jensen, Chairman, bought 30,000 shares in the company on the 29th September 2016 at a price of 19.25p. The Director ...

Director/PDMR Shareholding

RNS Number: 2273L Allergy Therapeutics PLC 29 September 2016 29 September 2016 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director/PDMR Shareholding Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that the Board of Allergy Therapeutics was info...

Director Deals - Allergy Therapeutics PLC (AGY)

Nick Wykeman, Financial Director, bought 150,000 shares in the company on the 27th September 2016 at a price of 17.75p. T...

Director/PDMR Shareholding

RNS Number: 0114L Allergy Therapeutics PLC 28 September 2016 28 September 2016 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director/PDMR Shareholding Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that the Board of Allergy Therapeutics was infor...

Allergy Therapeutics tipped to bounce back

Investors may have to wait longer for a return to profit, argues one expert, although there's still potential for the share pric...

Director Deals - Allergy Therapeutics PLC (AGY)

Manuel Llobet, Chief Executive Officer, bought 100,000 shares in the company on the 26th September 2016 at a price of 18.0...

Director/PDMR Shareholding

RNS Number: 8300K Allergy Therapeutics PLC 26 September 2016 26 September 2016 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director/PDMR Shareholding Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that on 26 September 2016, the Board of Allergy ...

Hardman Research: Performance drives market share

RNS Number: 8070K Allergy Therapeutics PLC 26 September 2016 Hardman Research: Performance drives market share Excellent performance drives market share gains: Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on...

Fundamental DataMore

EPS-2.29
Dividend yield0 %

Equity Research (AGY)

hardman & co
Allergy Therapeutics plc
07/06/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. It’s lead product, Pollinex Quattro is available in Europe only on a ‘Named Patient’ basis. However,...
edison investment research
Allergy Therapeutics plc
06/05/2016
Edison Investment Research is terminating coverage on Allergy Therapeutics (AGY). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should...
hardman & co
Allergy Therapeutics plc
06/04/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The first half of fiscal 2016 has been fueled by the progress made in the clinical trials required to get...

Latest discussion posts More

  • Numis

    From Citywire: "Allergy Therapeutics trading at a significant discount: buy Allergy Therapeutics (AGY) is trading at a discount to peers and additional upside is in the ...
    27-Sep-2016
    nk1999
  • TV Interviews

    Morning - new films for Allergy. Results film and re-edited Overview film www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/
    27-Sep-2016
    Dino78
  • Two words that matter most

    I have been traveling all day but see another fall in the price. May I ask if the 17.38 were in fact Buy trades and not a reported sell trades? Any update appreciated. AGY ...
    26-Sep-2016
    Baffler

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.27%
BP17%
VODAFONE GRP.15%
HSBC HLDGS.UK13%
BARCLAYS13%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY